| 摘要 |
An isolated antibody or one of its functional fragments able to bond with human Insulin-like Growth Factor-I Receptor (IGF-IR) and, if necessary, inhibit the natural fixing of IGF1 and/or IGF2 ligands and/or capable of specifically inhibiting the tyrosine kinase activity of the IGF-IR receptor, is new. A new isolated antibody or one of its functional fragments is able to bond with human Insulin-like Growth Factor-I Receptor (IGF-IR) and, if necessary, inhibit the natural fixing of IGF1 and/or IGF2 ligands and/or is capable of specifically inhibiting the tyrosine kinase activity of the IGF-IR receptor. It comprises a light chain with at least one CDR (complementarity-determining region) determining the complementarity selected from the CDRs of SEQ ID No: 1, 2, 3 sequences or at least one CDR with its sequence being at least 80 per cent identical after optimal alignment with the SEQ ID No: 1, 2 or 3 sequences, and/or a heavy chain with at least one CDR selected from the CDRs of sequences SEQ ID No: 4, 5 and 6, or at least one CDR having at least 80 per cent identity after optimal alignment with the SEQ ID No: 4, 5 and 6 sequences. The antibody, called 13F5, comprises a heavy chain with the amino-acid sequence SEQ ID No: 20 and a light chain containing the amino acid sequence SEQ ID No: 19. All the sequences are given in the specification. - ACTIVITY : Cytostatic. - MECHANISM OF ACTION : IGF-IR antagonist. |
